Wave, Deep Genomics partner for neuromuscular disease targets

Neuromuscular disease company Wave Life Sciences Ltd. (NASDAQ:WVE) and Deep Genomics Inc. (Toronto, Ontario) partnered to identify and validate targets for genetic neuromuscular disorders.

The companies will evaluate oligonucleotides against potential therapeutic targets implicated in neuromuscular diseases. Deep Genomics' machine learning platform will identify "cause and effect relationships" among targets that regulate splicing. Wave will use its chemistry platform to validate targets and aims to expand its pipeline of rationally designed oligonucleotides...